Abstract:Abstract Abstract 4710 Acute promyelocytic leukemia (APL) represents 3.3%-17.4% of acute leukemia in adults. With the application of all-trans retinoic acid (ATRA), more than 85% patient can achieve complete remission, however, high rates of relapse still exist if ATRA is used alone. Primary resistance of ATRA in PML-RARα positive APL is rare during induction therapy but the incidence markedly increases after second relapse and results in poor long time survival of patient. Matrine (MAT) is the effective constituent of Radix Sophorae Flavescentis, a commonly used traditional chinese drug, and has proven ability to inhibit carcinoma cell proliferation and can induce differentiation and apoptosis of K562 cells, however its effect on the differentiation of APL cells, especially on ATRA resistant APL cells is unclear. The aim of our research is to explore the effect of MAT on alleviating retinoic acid resistance in APL cells and address possible mechanisms involved. The characteristics of ATRA sensitive APL cell strain NB4 and resistant APL cell strains NB4-R1 and NB4-R2 were described in our former studies. Dose escalation studies using MAT and ATRA was investigated using methyl thiazolyl tetrazolium (MTT) test. The toxicity of MAT increases with increasing concentration of MAT from 0.001 mmol/L to 10 mmol/L, and the 0.1mmol/L was chosen with its inhibition ratio < 10%. IC50 of ATRA was obtained by drawing the restrain curve; the resistance coefficient (RC) of NB4-R1 and NB4-R2 to ATRA was obtained by the ratios of their IC50 to that of NB4 cell, respectively. And the reversal index (RI) was obtained by the ratios of RC of resistant cell line cells cultured with or without 0.1 mmol/L MAT for 72h. Cell differentiation was evaluated by nitro blue tetrazolium chioride (NBT) test and cell morphology. Differential effects on cell differentiation between MAT combined with 1 umol/L ATRA and controls were observed. For these studies, 1umol/L of ATRA was chosen according to the result of IC50 test, which had low toxicity to resistance cell line cells, with the inhibition ratio < 10%. Apoptosis rate of cells treated with MAT combined with 1 umol/L ATRA was tested by flow cytometry with Annexin V-PI staining. Nested PCR was used for PML/RARa PCR reaction. Our results showed, after treated with ATRA along with 0.1 mmol/L MAT, the resistance factor of NB4-R1 to ATRA decreased markedly (RI=4.96±1.15), but no difference was shown in NB4-R2 cells (RI=0.66±0.17). The positive ratio of NBT and the morphologic changes indicated that the differentiation ability of NB4 and NB4-R1was enhanced significantly with the increasing concentration of MAT combined with 1 umol/L ATRA, which reached the peak at 0.1mmol/L (Figure). The apoptosis ratio (Annexin V-FITC kit) of NB4 and NB4-R1 were also increased with increasing concentration of MAT combined with 1 umol/L ATRA, while no changes were observed using the NB4-R2 cell line. The expression of PML-RARα fusion became weak in NB4 and NB4-R1 cells after treated with 0.1 umol/L ATRA alone, and decreased notably when co-treated with 0.1 mmol/L MAT for 72h in NB4-R1, while the fusion gene expression remained negative in NB4-R2 cells exposed to both drugs. From this study, we conclude that MAT, when used together with ATRA as a low non-toxic dose, can improve the differentiation of NB4 cells and inverse the retinoic acid resistance of NB4-R1 cells, but it has no function on NB4-R2 cells. As the mechanism of ATRA resistance in NB4-R1 and NB4-R2 cells is different, with resistance to the former ascribed to abnormal cyclic adenosine monophosphate (cAMP) mediated pathways, leading to altered differentiation of NB4-R1 which can be corrected when cells are cocultured with cAMP and ATRA, and resistance of NB4-R2 is owing to the variation of PML-RARα, which can only be alleviated in the existence of RXR receptor specific agonist, MAT may play its anti-ATRA resistance role in an ATRA dependent pathway, and lead to the inhibition of the PML-RARα fusion gene. This indicates a possible application of MAT in ATRA resistance therapy. Further research will focus on the mechanism of MAT in the regulation and differentiation as well as apoptosis of APL cells. Disclosures: No relevant conflicts of interest to declare.

Myeloid maturity: ATRA to enhance anti-PD-1?

[Study on Matrine Alleviating Retinoic Acid Resistance in Acute Promyelocytic Leukemia].

Low Dose All-Trans Retinoic Acid and Androgen Therapy for Patients with Myelodysplastic Syndrome

Long-Term Efficacy of Low-Dose All-Trans Retinoic Acid Plus Individually Adapted Chemotherapy Induction Followed by Arsenic Trioxide Based Post-Remission Therapy in Adults with Newly Diagnosed Acute Promyelocytic Leukemia

Combination of Decitabine and ATRA in Newly Diagnosed Myelodysplastic Syndromes Subtype EB-Interim Analysis of a Multicenter, Randomized, Open-Label Trial

The Clinical Efficacy of All-Trans Retinoic Acid Plus Arsenic Trioxide in 177 Newly Diagnosed Acute Promyelocytic Leukemia Patients

Delivery of All-Trans-retinoic-acid (ATRA) in Liposomes Modulated MDSCs and T-cell Activities in the Tumor Microenvironment.

Myeloid maturation potentiates STAT3-mediated atypical IFN-γ signaling and upregulation of PD-1 ligands in AML and MDS

All-trans retinoic acid enhances murine dendritic cell migration to draining lymph nodes via the balance of matrix metalloproteinases and their inhibitors.

Abstract 2124: ATRA mediated inhibition of myeloid-derived suppressor cells overcomes resistance to immune checkpoint inhibition in murine models of LKB1-deficient non-small cell lung cancer

All-trans retinoic acid improves NSD2-mediated RARα phase separation and efficacy of anti-CD38 CAR T-cell therapy in multiple myeloma

All-trans retinoic acid in hematologic disorders: not just acute promyelocytic leukemia

Autophagy and Ubiquitin-Mediated Proteolytic Degradation of PML/Rarα Fusion Protein in Matrine-Induced Differentiation Sensitivity Recovery of ATRA-Resistant APL (NB4-LR1) Cells: in Vitro and in Vivo Studies

Effect of Matrine on Alleviating Retinoic Acid Resisted Acute Promyelocytic Leukemia

Sustained Drug Release From Liposomes for the Remodeling of Systemic Immune Homeostasis and the Tumor Microenvironment

Combining All-Trans Retinoid Acid Treatment Targeting Myeloid-Derived Suppressive Cells with Cryo-Thermal Therapy Enhances Antitumor Immunity in Breast Cancer.

Abstract 5157: ATRA treatment induces an interferon response to reprogram the immunosuppressive tumor microenvironment and overcomes resistance to immune checkpoint inhibition in murine models of LKB1 deficient non small cell lung cancer

Targeting DHODH reveals therapeutic opportunities in ATRA-resistant acute promyelocytic leukemia

Isotope-coding Quatitative Proteomics Reveals That Peroxiredoxins and Other Mitochondrial Effectors, Play a Role in Proliferation and Apoptosis of Acute Promyelocytic Leukemia Cells Following ATRA Treatment.

Abstract 4032: ATRA induces an interferon response to reprogram the immunosuppressive tumor microenvironment and overcomes resistance to immune checkpoint inhibition in murine models of LKB1-deficient non-small cell lung cancer

Dihydromyricetin sensitizes human acute myeloid leukemia cells to retinoic acid-induced myeloid differentiation by activating STAT1